Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.
Pfizer (NYSE:PFE) revealed Monday that tilrekimig (PF-07275315) met its primary efficacy endpoint in a Phase 2 study, showing a statistically significant increase in the percentage of patients achieving 75% skin clearance (EASI-75) at Week 16 compared to placebo.
The drug is a potential first-in-class trispecific antibody designed to simultaneously target three key inflammatory pathways: IL-4, IL-13, and TSLP.
In the dose-ranging portion of the trial, the monthly middle and high doses showed placebo-adjusted EASI-75 rates of 51.9% and 49.4%, respectively.
Pfizer management noted that these results suggest tilrekimig could offer meaningful improvements over current standard-of-care biologics.
Unlike some existing treatments, tilrekimig’s mechanism targets multiple drivers of Type 2 immune responses without affecting receptors on healthy cells.